{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T20:43:28Z","timestamp":1790196208732,"version":"4.1.0"},"reference-count":120,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice &amp; Research Clinical Haematology"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.beha.2021.101276","type":"journal-article","created":{"date-parts":[[2021,6,3]],"date-time":"2021-06-03T00:04:42Z","timestamp":1622678682000},"page":"101276","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"title":["Immunologic effects on the haematopoietic stem cell in marrow failure"],"prefix":"10.1016","volume":"34","author":[{"given":"Bhavisha A","family":"Patel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Giudice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neal S","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"17","key":"10.1016\/j.beha.2021.101276_bib1","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1056\/NEJMra1413485","article-title":"Aplastic anaemia","volume":"379","author":"Young","year":"2018","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.beha.2021.101276_bib2","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1111\/bjh.14535","article-title":"The genomics of inherited bone marrow failure: from mechanism to the clinic","volume":"177","author":"Wegman-Ostrosky","year":"2017","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1016\/j.beha.2021.101276_bib3","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1182\/blood.V88.6.1983.bloodjournal8861983","article-title":"A severe and consistent deficit in marrow and circulating primitive haematopoietic cells (long-term culture-initiating cells) in acquired aplastic anaemia","volume":"88","author":"Maciejewski","year":"1996","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.beha.2021.101276_bib4","doi-asserted-by":"crossref","first-page":"4474","DOI":"10.1182\/blood.V88.12.4474.bloodjournal88124474","article-title":"Quantitative analysis of cobblestone area-forming cells in bone marrow of patients with aplastic anaemia by limiting dilution assay","volume":"88","author":"Schrezenmeier","year":"1996","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.beha.2021.101276_bib5","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1002\/(SICI)1096-8652(199608)52:4<264::AID-AJH5>3.0.CO;2-Q","article-title":"Deficiency of CD34+ c-kit+ and CD34+38- haematopoietic precursors in aplastic anaemia after immunosuppressive treatment","volume":"52","author":"Manz","year":"1996","journal-title":"American journal of haematology"},{"issue":"2","key":"10.1016\/j.beha.2021.101276_bib6","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/1096-8652(200010)65:2<123::AID-AJH6>3.0.CO;2-M","article-title":"Sustained long-term haematologic recovery despite a marked quantitative defect in the stem cell compartment of patients with aplastic anaemia after immunosuppressive therapy","volume":"65","author":"Maciejewski","year":"2000","journal-title":"American journal of haematology"},{"issue":"8","key":"10.1016\/j.beha.2021.101276_bib7","first-page":"829","article-title":"Response of CFU-GM to increasing doses of rhGM-CSF in patients with aplastic anaemia","volume":"19","author":"Bacigalupo","year":"1991","journal-title":"Experimental haematology"},{"issue":"1","key":"10.1016\/j.beha.2021.101276_bib8","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1002\/ajh.2830350103","article-title":"Responsiveness of bone marrow erythropoietic stem cells (CFU-E and BFU-E) to recombinant human erythropoietin (rh-Ep) in vitro in aplastic anaemia and myelodysplastic syndrome","volume":"35","author":"Aoki","year":"1990","journal-title":"American journal of haematology"},{"issue":"5702","key":"10.1016\/j.beha.2021.101276_bib9","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1136\/bmj.2.5702.131","article-title":"Bone marrow graft in man after conditioning by antilymphocytic serum","volume":"2","author":"Math\u00e9","year":"1970","journal-title":"Br Med J"},{"issue":"2","key":"10.1016\/j.beha.2021.101276_bib10","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1182\/blood.V87.2.491.bloodjournal872491","article-title":"Complete remission in severe aplastic anaemia after high-dose cyclophosphamide without bone marrow transplantation","volume":"87","author":"Brodsky","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.beha.2021.101276_bib11","first-page":"271","article-title":"Treatment of severe aplastic anaemia with high-dose methylprednisolone and antilymphocyte globulin","volume":"148","author":"Marmont","year":"1984","journal-title":"Prog Clin Biol Res"},{"issue":"9","key":"10.1016\/j.beha.2021.101276_bib12","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1001\/jama.289.9.1130","article-title":"Antithymocyte globulin and cyclosporine for severe aplastic anaemia: association between haematologic response and long-term outcome","volume":"289","author":"Rosenfeld","year":"2003","journal-title":"Jama"},{"issue":"6","key":"10.1016\/j.beha.2021.101276_bib13","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1182\/blood-2011-12-274019","article-title":"How I treat acquired aplastic anaemia","volume":"120","author":"Scheinberg","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.beha.2021.101276_bib14","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ejca.2019.07.014","article-title":"Haematological immune-related adverse events with immune checkpoint inhibitors, how to manage?","volume":"122","author":"Michot","year":"2019","journal-title":"Eur J Canc"},{"issue":"4","key":"10.1016\/j.beha.2021.101276_bib15","doi-asserted-by":"crossref","first-page":"E89","DOI":"10.1002\/ajh.25725","article-title":"Allogenic haematopoietic stem cell transplantation for prolonged bone marrow aplasia after chimeric antigen receptor (CAR) T-cell therapy for relapsed diffuse large B-cell lymphoma","volume":"95","author":"Qasrawi","year":"2020","journal-title":"American journal of haematology"},{"issue":"8","key":"10.1016\/j.beha.2021.101276_bib16","doi-asserted-by":"crossref","first-page":"2890","DOI":"10.1073\/pnas.73.8.2890","article-title":"Aplastic anaemia: presence in human bone marrow of cells that suppress myelopoiesis","volume":"73","author":"Kagan","year":"1976","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1016\/j.beha.2021.101276_bib17","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1056\/NEJM197701062960103","article-title":"Suppression of erythroid-colony formation by lymphocytes from patients with aplastic anaemia","volume":"296","author":"Hoffman","year":"1977","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.beha.2021.101276_bib18","first-page":"649","article-title":"[Changes of subsets of DC1 in the bone marrow of severe aplastic anaemia patients]","volume":"25","author":"He","year":"2004","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"issue":"2","key":"10.1016\/j.beha.2021.101276_bib19","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22020705","article-title":"Bone marrow failure syndromes, overlapping diseases with a common cytokine signature","volume":"22","author":"Giudice","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"20","key":"10.1016\/j.beha.2021.101276_bib20","doi-asserted-by":"crossref","first-page":"4175","DOI":"10.1182\/blood-2010-01-266098","article-title":"Th17 immune responses contribute to the pathophysiology of aplastic anaemia","volume":"116","author":"de Latour","year":"2010","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.beha.2021.101276_bib21","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1182\/blood-2011-08-368308","article-title":"Functional characterization of CD4+ T cells in aplastic anaemia","volume":"119","author":"Kordasti","year":"2012","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.beha.2021.101276_bib22","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1182\/blood-2002-01-0236","article-title":"Oligoclonal and polyclonal CD4 and CD8 lymphocytes in aplastic anaemia and paroxysmal nocturnal haemoglobinuria measured by V beta CDR3 spectratyping and flow cytometry","volume":"100","author":"Risitano","year":"2002","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.beha.2021.101276_bib23","doi-asserted-by":"crossref","first-page":"759","DOI":"10.3324\/haematol.2017.176701","article-title":"Deep sequencing and flow cytometric characterization of expanded effector memory CD8(+)CD57(+) T cells frequently reveals T-cell receptor Vbeta oligoclonality and CDR3 homology in acquired aplastic anaemia","volume":"103","author":"Giudice","year":"2018","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.beha.2021.101276_bib24","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1073\/pnas.82.1.188","article-title":"Interferon is a mediator of haematopoietic suppression in aplastic anaemia in vitro and possibly in vivo","volume":"82","author":"Zoumbos","year":"1985","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"10.1016\/j.beha.2021.101276_bib25","doi-asserted-by":"crossref","first-page":"4149","DOI":"10.1182\/blood.V87.10.4149.bloodjournal87104149","article-title":"Interferon-gamma constitutively expressed in the stromal microenvironment of human marrow cultures mediates potent haematopoietic inhibition","volume":"87","author":"Selleri","year":"1996","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.beha.2021.101276_bib26","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1182\/blood-2006-03-010777","article-title":"Current concepts in the pathophysiology and treatment of aplastic anaemia","volume":"108","author":"Young","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.beha.2021.101276_bib27","doi-asserted-by":"crossref","first-page":"330","DOI":"10.3389\/fimmu.2016.00330","article-title":"Haematopoietic stem cell regulation by type I and II interferons in the pathogenesis of acquired aplastic anaemia","volume":"7","author":"Smith","year":"2016","journal-title":"Front Immunol"},{"issue":"24","key":"10.1016\/j.beha.2021.101276_bib28","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1182\/blood-2015-06-652453","article-title":"IFN-\u03b3-mediated haematopoietic cell destruction in murine models of immune-mediated bone marrow failure","volume":"126","author":"Chen","year":"2015","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.beha.2021.101276_bib29","doi-asserted-by":"crossref","first-page":"4083","DOI":"10.4238\/2014.May.30.3","article-title":"Fas\/FasL in the immune pathogenesis of severe aplastic anaemia","volume":"13","author":"Liu","year":"2014","journal-title":"Genet Mol Res"},{"issue":"12","key":"10.1016\/j.beha.2021.101276_bib30","doi-asserted-by":"crossref","first-page":"5984","DOI":"10.4049\/jimmunol.168.12.5984","article-title":"Cutting edge: activation of the p38 mitogen-activated protein kinase signaling pathway mediates cytokine-induced hemopoietic suppression in aplastic anaemia","volume":"168","author":"Verma","year":"2002","journal-title":"J Immunol"},{"issue":"25","key":"10.1016\/j.beha.2021.101276_bib31","doi-asserted-by":"crossref","first-page":"3699","DOI":"10.1182\/blood-2014-01-549527","article-title":"IFN-\u03b3 causes aplastic anaemia by altering haematopoietic stem\/progenitor cell composition and disrupting lineage differentiation","volume":"124","author":"Lin","year":"2014","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.beha.2021.101276_bib32","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1182\/blood-2013-04-494930","article-title":"STAT3 mutations indicate the presence of subclinical T-cell clones in a subset of aplastic anaemia and myelodysplastic syndrome patients","volume":"122","author":"Jerez","year":"2013","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.beha.2021.101276_bib33","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1038\/s41375-021-01231-3","article-title":"Somatic mutations in lymphocytes in patients with immune-mediated aplastic anaemia","volume":"35","author":"Lundgren","year":"2021","journal-title":"Leukaemia"},{"issue":"19","key":"10.1016\/j.beha.2021.101276_bib34","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1182\/blood-2018-11-884486","article-title":"Eltrombopag maintains human haematopoietic stem and progenitor cells under inflammatory conditions mediated by IFN-\u03b3","volume":"133","author":"Alvarado","year":"2019","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.beha.2021.101276_bib35","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1182\/blood.2019000940","article-title":"Secondary myelodysplastic syndrome and leukaemia in acquired aplastic anaemia and paroxysmal nocturnal haemoglobinuria","volume":"136","author":"Sun","year":"2020","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.beha.2021.101276_bib36","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1182\/blood-2018-05-844928","article-title":"Macrophage TNF-\u03b1 licenses donor T cells in murine bone marrow failure and can be implicated in human aplastic anaemia","volume":"132","author":"Sun","year":"2018","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.beha.2021.101276_bib37","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.critrevonc.2009.12.001","article-title":"Abnormal immunity and stem\/progenitor cells in acquired aplastic anaemia","volume":"75","author":"Li","year":"2010","journal-title":"Crit Rev Oncol-Hematol"},{"issue":"3","key":"10.1016\/j.beha.2021.101276_bib38","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/cei.12605","article-title":"The complex pathophysiology of acquired aplastic anaemia","volume":"180","author":"Zeng","year":"2015","journal-title":"Clin Exp Immunol"},{"issue":"4","key":"10.1016\/j.beha.2021.101276_bib39","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1111\/bjh.16651","article-title":"Deficit of circulating CD19(+) CD24(hi) CD38(hi) regulatory B cells in severe aplastic anaemia","volume":"190","author":"Zaimoku","year":"2020","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.beha.2021.101276_bib40","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1056\/NEJMoa1103975","article-title":"Horse versus rabbit antithymocyte globulin in acquired aplastic anaemia","volume":"365","author":"Scheinberg","year":"2011","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.beha.2021.101276_bib41","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1038\/sj.leu.2404683","article-title":"Mechanisms of action of antithymocyte globulin: T-cell depletion and beyond","volume":"21","author":"Mohty","year":"2007","journal-title":"Leukaemia"},{"issue":"16","key":"10.1016\/j.beha.2021.101276_bib42","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJMoa1613878","article-title":"Eltrombopag added to standard immunosuppression for aplastic anaemia","volume":"376","author":"Townsley","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2021.101276_bib43","doi-asserted-by":"crossref","unstructured":"Yihong Guan P, Metis Hasipek, PhD , Bhumika J. Patel, MD , Dale Grabowski, BS , Anand D. Tiwari, PhD , Sunisa Kongkiatkamon, MD , Cassandra M Kerr, MS , Aziz Nazha, MD , Yogenthiran Saunthararajah, MD , Mikkael A. Sekeres, MD MS , Jaroslaw P. Maciejewski, MD PhD , Babal K. Jha, PhD. TET2 inhibitory effects of eltrombopag contribute its haematopoietic activity American Society of Haematology Conference2020.","DOI":"10.1182\/blood-2020-142875"},{"issue":"10","key":"10.1016\/j.beha.2021.101276_bib44","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.3324\/haematol.2017.163675","article-title":"Rapamycin is highly effective in murine models of immune-mediated bone marrow failure","volume":"102","author":"Feng","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.beha.2021.101276_bib45","first-page":"31","article-title":"Immunological derangement in hypocellular myelodysplastic syndromes","volume":"8","author":"Serio","year":"2014","journal-title":"Transl Med UniSa"},{"issue":"4","key":"10.1016\/j.beha.2021.101276_bib46","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1385\/MO:22:4:407","article-title":"Spontaneous remission in adults with primary myelodysplastic syndromes: incidence and characteristics of patients","volume":"22","author":"Marisavljevi\u0107","year":"2005","journal-title":"Med Oncol"},{"issue":"2","key":"10.1016\/j.beha.2021.101276_bib47","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.hoc.2009.01.015","article-title":"Hypocellular myelodysplasia","volume":"23","author":"Sloand","year":"2009","journal-title":"Hematol Oncol Clin N Am"},{"issue":"5","key":"10.1016\/j.beha.2021.101276_bib48","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1053\/j.seminoncol.2011.04.006","article-title":"Immunologic aspects of hypoplastic myelodysplastic syndrome","volume":"38","author":"Calado","year":"2011","journal-title":"Semin Oncol"},{"issue":"10","key":"10.1016\/j.beha.2021.101276_bib49","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1038\/s41375-019-0457-1","article-title":"Clinical, histopathological and molecular characterization of hypoplastic myelodysplastic syndrome","volume":"33","author":"Bono","year":"2019","journal-title":"Leukaemia"},{"issue":"20","key":"10.1016\/j.beha.2021.101276_bib50","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1182\/bloodadvances.2018015834","article-title":"Molecular pathophysiology of the myelodysplastic syndromes: insights for targeted therapy","volume":"2","author":"Aleshin","year":"2018","journal-title":"Blood advances"},{"issue":"10","key":"10.1016\/j.beha.2021.101276_bib51","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.leukres.2010.03.001","article-title":"Hypoplastic myelodysplastic syndrome (h-MDS) is a distinctive clinical entity with poorer prognosis and frequent karyotypic and FISH abnormalities compared to aplastic anaemia (AA)","volume":"34","author":"Koh","year":"2010","journal-title":"Leukaemia research"},{"issue":"39","key":"10.1016\/j.beha.2021.101276_bib52","doi-asserted-by":"crossref","first-page":"63177","DOI":"10.18632\/oncotarget.11050","article-title":"Distinct mutation profile and prognostic relevance in patients with hypoplastic myelodysplastic syndromes (h-MDS)","volume":"7","author":"Yao","year":"2016","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.beha.2021.101276_bib53","doi-asserted-by":"crossref","first-page":"449","DOI":"10.3324\/haematol.2009.006080","article-title":"Autoimmune mechanisms in the pathophysiology of myelodysplastic syndromes and their clinical relevance","volume":"94","author":"Barrett","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.beha.2021.101276_bib54","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.critrevonc.2017.12.013","article-title":"Immune dysregulation in myelodysplastic syndrome: clinical features, pathogenesis and therapeutic strategies","volume":"122","author":"Wang","year":"2018","journal-title":"Crit Rev Oncol-Hematol"},{"issue":"9431","key":"10.1016\/j.beha.2021.101276_bib55","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0140-6736(04)16724-X","article-title":"In-vivo dominant immune responses in aplastic anaemia: molecular tracking of putatively pathogenetic T-cell clones by TCR beta-CDR3 sequencing","volume":"364","author":"Risitano","year":"2004","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.beha.2021.101276_bib56","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.exphem.2009.12.004","article-title":"Abnormalities of the alphabeta T-cell receptor repertoire in advanced myelodysplastic syndrome","volume":"38","author":"Campregher","year":"2010","journal-title":"Experimental haematology"},{"issue":"4","key":"10.1016\/j.beha.2021.101276_bib57","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1038\/sj.leu.2404590","article-title":"Prevalence and clinical association of clonal T-cell expansions in Myelodysplastic Syndrome","volume":"21","author":"Epling-Burnette","year":"2007","journal-title":"Leukaemia"},{"issue":"1","key":"10.1016\/j.beha.2021.101276_bib58","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2174\/157488807779316982","article-title":"Function and malfunction of haematopoietic stem cells in primary bone marrow failure syndromes","volume":"2","author":"Risitano","year":"2007","journal-title":"Curr Stem Cell Res Ther"},{"issue":"8","key":"10.1016\/j.beha.2021.101276_bib59","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1038\/sj.leu.2401084","article-title":"Measurement of secondary colony formation after 5 weeks in long-term cultures in patients with myelodysplastic syndrome","volume":"12","author":"Sato","year":"1998","journal-title":"Leukaemia"},{"issue":"3","key":"10.1016\/j.beha.2021.101276_bib60","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1046\/j.1365-2141.1996.4323240.x","article-title":"Induction of nitric oxide synthase is involved in the mechanism of Fas-mediated apoptosis in haemopoietic cells","volume":"99","author":"Selleri","year":"1997","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.beha.2021.101276_bib61","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1182\/blood.V99.5.1594","article-title":"In vitro proliferation and differentiation of erythroid progenitors from patients with myelodysplastic syndromes: evidence for Fas-dependent apoptosis","volume":"99","author":"Claessens","year":"2002","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.beha.2021.101276_bib62","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1016\/j.exphem.2007.09.007","article-title":"Apoptosis and antiapoptotic mechanisms in the progression of myelodysplastic syndrome","volume":"35","author":"Kerbauy","year":"2007","journal-title":"Experimental haematology"},{"issue":"10","key":"10.1016\/j.beha.2021.101276_bib63","doi-asserted-by":"crossref","first-page":"3058","DOI":"10.1182\/blood.V98.10.3058","article-title":"Expression of tumor necrosis factor-related apoptosis-inducing ligand, Apo2L, and its receptors in myelodysplastic syndrome: effects on in vitro hemopoiesis","volume":"98","author":"Zang","year":"2001","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.beha.2021.101276_bib64","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1182\/blood-2004-05-2017","article-title":"Preferential suppression of trisomy 8 compared with normal haematopoietic cell growth by autologous lymphocytes in patients with trisomy 8 myelodysplastic syndrome","volume":"106","author":"Sloand","year":"2005","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.beha.2021.101276_bib65","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1182\/blood-2010-04-277921","article-title":"T-cell immune responses to Wilms tumor 1 protein in myelodysplasia responsive to immunosuppressive therapy","volume":"117","author":"Sloand","year":"2011","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.beha.2021.101276_bib66","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1002\/cncr.10915","article-title":"Effects of cyclosporine on haematopoietic and immune functions in patients with hypoplastic myelodysplasia: in vitro and in vivo studies","volume":"95","author":"Selleri","year":"2002","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.beha.2021.101276_bib67","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/j.1365-2141.2009.07593.x","article-title":"IL-17-producing CD4(+) T cells, pro-inflammatory cytokines and apoptosis are increased in low risk myelodysplastic syndrome","volume":"145","author":"Kordasti","year":"2009","journal-title":"Br J Haematol"},{"issue":"11","key":"10.1016\/j.beha.2021.101276_bib68","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/j.exphem.2005.07.005","article-title":"Killer immunoglobulin-like receptor genotype in immune-mediated bone marrow failure syndromes","volume":"33","author":"Howe","year":"2005","journal-title":"Experimental haematology"},{"issue":"1","key":"10.1016\/j.beha.2021.101276_bib69","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/j.1365-2141.1995.tb05277.x","article-title":"Increased expression of Fas antigen on bone marrow CD34+ cells of patients with aplastic anaemia","volume":"91","author":"Maciejewski","year":"1995","journal-title":"Br J Haematol"},{"issue":"11","key":"10.1016\/j.beha.2021.101276_bib70","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1182\/blood.V85.11.3183.bloodjournal85113183","article-title":"Fas antigen expression on CD34+ human marrow cells is induced by interferon gamma and tumor necrosis factor alpha and potentiates cytokine-mediated haematopoietic suppression in vitro","volume":"85","author":"Maciejewski","year":"1995","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.beha.2021.101276_bib71","doi-asserted-by":"crossref","first-page":"4749","DOI":"10.1182\/blood.V90.12.4749","article-title":"Inhibition of interferon regulatory factor-1 expression results in predominance of cell growth stimulatory effects of interferon-gamma due to phosphorylation of Stat1 and Stat3","volume":"90","author":"Sato","year":"1997","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.beha.2021.101276_bib72","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13010132","article-title":"Hypoplastic myelodysplastic syndromes: just an overlap syndrome?","volume":"13","author":"Fattizzo","year":"2021","journal-title":"Cancers"},{"issue":"3","key":"10.1016\/j.beha.2021.101276_bib73","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/BF02982044","article-title":"Biological significance of proliferation, apoptosis, cytokines, and monocyte\/macrophage cells in bone marrow biopsies of 145 patients with myelodysplastic syndrome","volume":"75","author":"Allampallam","year":"2002","journal-title":"International journal of haematology"},{"issue":"3","key":"10.1016\/j.beha.2021.101276_bib74","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/nri2506","article-title":"Myeloid-derived suppressor cells as regulators of the immune system","volume":"9","author":"Gabrilovich","year":"2009","journal-title":"Nat Rev Immunol"},{"issue":"8","key":"10.1016\/j.beha.2021.101276_bib75","doi-asserted-by":"crossref","first-page":"3434","DOI":"10.1182\/blood-2008-02-139824","article-title":"Inhibition of the TGF-beta receptor I kinase promotes haematopoiesis in MDS","volume":"112","author":"Zhou","year":"2008","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.beha.2021.101276_bib76","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s11899-008-0005-y","article-title":"Immunosuppressive therapy for myelodysplastic syndromes: refining the indications","volume":"3","author":"Barrett","year":"2008","journal-title":"Curr Haematol Malig Rep"},{"issue":"4","key":"10.1016\/j.beha.2021.101276_bib77","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1053\/j.seminhematol.2012.07.004","article-title":"Immunomodulatory treatment of myelodysplastic syndromes: antithymocyte globulin, cyclosporine, and alemtuzumab","volume":"49","author":"Parikh","year":"2012","journal-title":"Seminars in haematology"},{"issue":"14","key":"10.1016\/j.beha.2021.101276_bib78","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1182\/bloodadvances.2018019414","article-title":"The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort","volume":"2","author":"Stahl","year":"2018","journal-title":"Blood advances"},{"issue":"13","key":"10.1016\/j.beha.2021.101276_bib79","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1182\/blood-2013-07-512442","article-title":"Can the revised IPSS predict response to erythropoietic-stimulating agents in patients with classical IPSS low or intermediate-1 MDS?","volume":"122","author":"Santini","year":"2013","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.beha.2021.101276_bib80","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.3324\/haematol.2020.249995","article-title":"Eltrombopag monotherapy can improve haematopoiesis in patients with low to intermediate risk-1 myelodysplastic syndrome","volume":"105","author":"Alana","year":"2020","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.beha.2021.101276_bib81","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1111\/j.1365-2141.2011.08683.x","article-title":"Role of immune responses in the pathogenesis of low-risk MDS and high-risk MDS: implications for immunotherapy","volume":"153","author":"Aggarwal","year":"2011","journal-title":"Br J Haematol"},{"issue":"9","key":"10.1016\/j.beha.2021.101276_bib82","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1182\/blood-2016-08-692590","article-title":"LGL leukaemia: from pathogenesis to treatment","volume":"129","author":"Lamy","year":"2017","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.beha.2021.101276_bib83","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/blood.V82.1.1.bloodjournal8211","article-title":"Clonal diseases of large granular lymphocytes","volume":"82","author":"Loughran","year":"1993","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.beha.2021.101276_bib84","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1182\/blood-2007-06-093823","article-title":"Antigen activation and impaired Fas-induced death-inducing signaling complex formation in T-large-granular lymphocyte leukaemia","volume":"111","author":"Yang","year":"2008","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.beha.2021.101276_bib85","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1182\/blood-2009-06-223719","article-title":"Platelet-derived growth factor mediates survival of leukaemic large granular lymphocytes via an autocrine regulatory pathway","volume":"115","author":"Yang","year":"2010","journal-title":"Blood"},{"issue":"42","key":"10.1016\/j.beha.2021.101276_bib86","doi-asserted-by":"crossref","first-page":"16308","DOI":"10.1073\/pnas.0806447105","article-title":"Network model of survival signaling in large granular lymphocyte leukaemia","volume":"105","author":"Zhang","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"10.1016\/j.beha.2021.101276_bib87","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1172\/JCI9940","article-title":"Inhibition of STAT3 signaling leads to apoptosis of leukaemic large granular lymphocytes and decreased Mcl-1 expression","volume":"107","author":"Epling-Burnette","year":"2001","journal-title":"J Clin Invest"},{"issue":"20","key":"10.1016\/j.beha.2021.101276_bib88","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1056\/NEJMoa1114885","article-title":"Somatic STAT3 mutations in large granular lymphocytic leukaemia","volume":"366","author":"Koskela","year":"2012","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.beha.2021.101276_bib89","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1182\/blood-2016-06-724856","article-title":"High incidence of activating STAT5B mutations in CD4-positive T-cell large granular lymphocyte leukaemia","volume":"128","author":"Andersson","year":"2016","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.beha.2021.101276_bib90","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1038\/leu.2012.350","article-title":"STAT3 mutations are highly specific for large granular lymphocytic leukaemia","volume":"27","author":"Fasan","year":"2013","journal-title":"Leukaemia"},{"issue":"6","key":"10.1016\/j.beha.2021.101276_bib91","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1182\/bloodadvances.2018027862","article-title":"Subclonal STAT3 mutations solidify clonal dominance","volume":"3","author":"Kerr","year":"2019","journal-title":"Blood advances"},{"issue":"7","key":"10.1016\/j.beha.2021.101276_bib92","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1182\/blood-2002-09-2898","article-title":"Impaired granulocytopoiesis in patients with chronic idiopathic neutropenia is associated with increased apoptosis of bone marrow myeloid progenitor cells","volume":"101","author":"Papadaki","year":"2003","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.beha.2021.101276_bib93","doi-asserted-by":"crossref","first-page":"2764","DOI":"10.1182\/blood-2010-07-296962","article-title":"How I treat LGL leukaemia","volume":"117","author":"Lamy","year":"2011","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.beha.2021.101276_bib94","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1038\/leu.2014.298","article-title":"Immunosuppressive therapy of LGL leukaemia: prospective multicenter phase II study by the Eastern Cooperative Oncology Group (E5998)","volume":"29","author":"Loughran","year":"2015","journal-title":"Leukaemia"},{"issue":"1","key":"10.1016\/j.beha.2021.101276_bib95","doi-asserted-by":"crossref","first-page":"e22","DOI":"10.1016\/S2352-3026(15)00227-6","article-title":"Alemtuzumab in T-cell large granular lymphocytic leukaemia: interim results from a single-arm, open-label, phase 2 study","volume":"3","author":"Dumitriu","year":"2016","journal-title":"The Lancet Haematology"},{"issue":"4","key":"10.1016\/j.beha.2021.101276_bib96","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1111\/bjh.17147","article-title":"Paroxysmal nocturnal haemoglobinuria (PNH): novel therapies for an ancient disease","volume":"191","author":"Luzzatto","year":"2020","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.beha.2021.101276_bib97","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1053\/j.seminhematol.2018.02.002","article-title":"Expanding complement therapeutics for the treatment of paroxysmal nocturnal haemoglobinuria","volume":"55","author":"Mastellos","year":"2018","journal-title":"Seminars in haematology"},{"issue":"12","key":"10.1016\/j.beha.2021.101276_bib98","doi-asserted-by":"crossref","first-page":"5123","DOI":"10.1172\/JCI123501","article-title":"Complement and inflammasome overactivation mediates paroxysmal nocturnal haemoglobinuria with autoinflammation","volume":"129","author":"H\u00f6chsmann","year":"2019","journal-title":"J Clin Invest"},{"issue":"5","key":"10.1016\/j.beha.2021.101276_bib99","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1182\/blood.V85.5.1354.bloodjournal8551354","article-title":"Aplastic anaemia and paroxysmal nocturnal haemoglobinuria: search for a pathogenetic link","volume":"85","author":"Griscelli-Bennaceur","year":"1995","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.beha.2021.101276_bib100","doi-asserted-by":"crossref","first-page":"534","DOI":"10.7326\/0003-4819-136-7-200204020-00011","article-title":"Acquired aplastic anaemia","volume":"136","author":"Young","year":"2002","journal-title":"Ann Intern Med"},{"issue":"10","key":"10.1016\/j.beha.2021.101276_bib101","doi-asserted-by":"crossref","first-page":"3848","DOI":"10.1182\/blood-2004-04-1472","article-title":"PIG-A mutations in normal haematopoiesis","volume":"105","author":"Hu","year":"2005","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.beha.2021.101276_bib102","doi-asserted-by":"crossref","first-page":"5036","DOI":"10.1182\/blood-2006-10-052381","article-title":"Highly homologous T-cell receptor beta sequences support a common target for autoreactive T cells in most patients with paroxysmal nocturnal haemoglobinuria","volume":"109","author":"Gargiulo","year":"2007","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.beha.2021.101276_bib103","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1038\/sj.leu.2403678","article-title":"Differential gene expression in haematopoietic progenitors from paroxysmal nocturnal haemoglobinuria patients reveals an apoptosis\/immune response in 'normal' phenotype cells","volume":"19","author":"Chen","year":"2005","journal-title":"Leukaemia"},{"key":"10.1016\/j.beha.2021.101276_bib104","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.exphem.2018.09.008","article-title":"Aptamer-based proteomics of serum and plasma in acquired aplastic anaemia","volume":"68","author":"Giudice","year":"2018","journal-title":"Experimental haematology"},{"issue":"2","key":"10.1016\/j.beha.2021.101276_bib105","first-page":"205","article-title":"Paroxysmal nocturnal haemoglobinuria: pathophysiology, natural history and treatment options in the era of biological agents","volume":"2","author":"Risitano","year":"2008","journal-title":"Biologics"},{"issue":"7","key":"10.1016\/j.beha.2021.101276_bib106","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1182\/blood.V96.7.2613","article-title":"Abnormal T-cell repertoire is consistent with immune process underlying the pathogenesis of paroxysmal nocturnal haemoglobinuria","volume":"96","author":"Karadimitris","year":"2000","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.beha.2021.101276_bib107","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1532\/IJH97.06144","article-title":"Immune pathogenesis of paroxysmal nocturnal haemoglobinuria","volume":"84","author":"Tiu","year":"2006","journal-title":"International journal of haematology"},{"issue":"1","key":"10.1016\/j.beha.2021.101276_bib108","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1189\/jlb.0105026","article-title":"T cells from paroxysmal nocturnal haemoglobinuria (PNH) patients show an altered CD40-dependent pathway","volume":"78","author":"Terrazzano","year":"2005","journal-title":"J Leukoc Biol"},{"issue":"4","key":"10.1016\/j.beha.2021.101276_bib109","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s00262-020-02482-2","article-title":"CD16 pre-ligation by defucosylated tumor-targeting mAb sensitizes human NK cells to \u03b3(c) cytokine stimulation via PI3K\/mTOR axis","volume":"69","author":"Capuano","year":"2020","journal-title":"Cancer Immunol Immunother"},{"issue":"13","key":"10.1016\/j.beha.2021.101276_bib110","doi-asserted-by":"crossref","first-page":"8832","DOI":"10.1073\/pnas.132254399","article-title":"CD25+CD4+ T cells contribute to the control of memory CD8+ T cells","volume":"99","author":"Murakami","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"10.1016\/j.beha.2021.101276_bib111","doi-asserted-by":"crossref","first-page":"477","DOI":"10.4049\/jimmunol.1601299","article-title":"T cell transcriptomes from paroxysmal nocturnal haemoglobinuria patients reveal novel signaling pathways","volume":"199","author":"Hosokawa","year":"2017","journal-title":"J Immunol"},{"key":"10.1016\/j.beha.2021.101276_bib112","doi-asserted-by":"crossref","first-page":"102548","DOI":"10.1016\/j.jaut.2020.102548","article-title":"Corrigendum to \"The pivotal role of CD69 in autoimmunity","volume":"114","author":"Gorabi","year":"2020","journal-title":"J Autoimmun"},{"issue":"1","key":"10.1016\/j.beha.2021.101276_bib113","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/cr.2009.139","article-title":"Complement and its role in innate and adaptive immune responses","volume":"20","author":"Dunkelberger","year":"2010","journal-title":"Cell Res"},{"key":"10.1016\/j.beha.2021.101276_bib114","doi-asserted-by":"crossref","first-page":"102528","DOI":"10.1016\/j.bcmd.2020.102528","article-title":"Frequency and perturbations of various peripheral blood cell populations before and after eculizumab treatment in paroxysmal nocturnal hemoglobinuria","volume":"87","author":"Gurnari","year":"2021","journal-title":"Blood Cells Mol Dis"},{"issue":"4","key":"10.1016\/j.beha.2021.101276_bib115","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1111\/j.1365-2567.2006.02467.x","article-title":"Levels of expression of complement regulatory proteins CD46, CD55 and CD59 on resting and activated human peripheral blood leucocytes","volume":"119","author":"Christmas","year":"2006","journal-title":"Immunology"},{"key":"10.1016\/j.beha.2021.101276_bib116","doi-asserted-by":"crossref","first-page":"102528","DOI":"10.1016\/j.bcmd.2020.102528","article-title":"Frequency and perturbations of various peripheral blood cell populations before and after eculizumab treatment in paroxysmal nocturnal haemoglobinuria","volume":"87","author":"Gurnari","year":"2021","journal-title":"Blood Cells Mol Dis"},{"issue":"12","key":"10.1016\/j.beha.2021.101276_bib117","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1056\/NEJMoa061648","article-title":"The complement inhibitor eculizumab in paroxysmal nocturnal haemoglobinuria","volume":"355","author":"Hillmen","year":"2006","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.beha.2021.101276_bib118","doi-asserted-by":"crossref","first-page":"4123","DOI":"10.1182\/blood-2007-06-095646","article-title":"Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal haemoglobinuria","volume":"110","author":"Hillmen","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.beha.2021.101276_bib119","series-title":"Paroxysmal nocturnal haemoglobinuria: stem cells and clonality","first-page":"111","author":"Brodsky","year":"2008"},{"key":"10.1016\/j.beha.2021.101276_bib120","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.3389\/fimmu.2019.01157","article-title":"Anti-complement treatment for paroxysmal nocturnal haemoglobinuria: time for proximal complement inhibition? A position paper from the SAAWP of the EBMT","volume":"10","author":"Risitano","year":"2019","journal-title":"Front Immunol"}],"container-title":["Best Practice &amp; Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692621000414?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692621000414?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:08:07Z","timestamp":1761498487000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692621000414"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":120,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["S1521692621000414"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2021.101276","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunologic effects on the haematopoietic stem cell in marrow failure","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Haematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beha.2021.101276","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101276"}}